Prostate Cancer Clinical Trials in Boston

Showing 81-100 of 288 trials

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

NCT06862856

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.

Prostate Cancer (Adenocarcinoma)Prostate Specific Antigen

Massachusetts General Hospital50 participantsStarted May 2025

Boston, Massachusetts, United States • Boston, Massachusetts, United States

RECRUITINGNA< 1 mile

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Pancreas CancerLung CancerRenal Cancer+10 more

Dana-Farber Cancer Institute397 participantsStarted Oct 2019

Boston, Massachusetts, United States • Boston, Massachusetts, United States

RECRUITING< 1 mile

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

NCT04472338

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Prostate Carcinoma

University of Washington450 participantsStarted May 2020

Duarte, California, United States • San Francisco, California, United States • Chicago, Illinois, United States +5 more locations

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Stereotactic Magnetic Resonance Guided Radiation Therapy

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Prostate Cancer Trials in Other Cities

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention

Multimodal Machine Learning Characterization of Solid Tumors

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase III Radium 223 mCRPC-PEACE III

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Other Conditions in Boston